Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) have been assigned a consensus rating of “Moderate Buy” from the twelve analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $54.90.

Several research analysts have recently weighed in on FTH shares. Loop Capital set a $50.00 target price on Sensei Biotherapeutics in a report on Thursday, May 28th. Citizens Jmp initiated coverage on Sensei Biotherapeutics in a research note on Monday, July 20th. They set an “outperform” rating and a $51.00 price objective on the stock. Robert W. Baird started coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They issued an “outperform” rating and a $57.00 target price for the company. HC Wainwright began coverage on Sensei Biotherapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $60.00 price target on the stock. Finally, Citigroup started coverage on shares of Sensei Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $55.00 price target on the stock.

Insiders Place Their Bets

In other news, CEO Anand Kiran Parikh purchased 2,806 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was acquired at an average price of $19.76 per share, with a total value of $55,446.56. Following the purchase, the chief executive officer directly owned 764,234 shares in the company, valued at approximately $15,101,263.84. This represents a 0.37% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Brian C. Stephenson purchased 9,391 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were purchased at an average price of $26.13 per share, with a total value of $245,386.83. Following the acquisition, the chief financial officer directly owned 26,804 shares in the company, valued at approximately $700,388.52. The trade was a 53.93% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 49,494 shares of company stock valued at $1,188,822 over the last ninety days. Company insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On Sensei Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its position in Sensei Biotherapeutics by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after purchasing an additional 1,100 shares during the period. Stempoint Capital LP acquired a new stake in shares of Sensei Biotherapeutics during the 1st quarter worth about $4,188,000. Bank of America Corp DE increased its position in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Finally, Vivo Capital LLC purchased a new stake in Sensei Biotherapeutics in the 1st quarter valued at about $22,758,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Stock Down 3.6%

Sensei Biotherapeutics stock opened at $24.59 on Thursday. The firm has a market cap of $32.95 million, a PE ratio of -0.17 and a beta of -0.25. Sensei Biotherapeutics has a 52-week low of $7.20 and a 52-week high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. Equities research analysts anticipate that Sensei Biotherapeutics will post -15.23 EPS for the current fiscal year.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.